| October 1, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| October 1, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 1, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 1, 2025 |
SNY |
Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
Trial Milestone |
Phase 2 |
| October 1, 2025 |
SNY |
A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo |
Trial Milestone |
Phase 2 |
| October 1, 2025 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 1, 2025 |
NVO |
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise |
Trial Milestone |
Phase 3 |
| October 1, 2025 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| October 1, 2025 |
VNDA |
8-K filed: Other event |
Filing |
— |
| October 1, 2025 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| October 1, 2025 |
IMTX |
6-K filed: Foreign issuer report |
Filing |
— |
| October 1, 2025 |
CLYM |
8-K filed: Leadership change |
Corporate |
— |
| October 1, 2025 |
CATX |
8-K filed: Other event |
Filing |
— |
| October 1, 2025 |
HALO |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 1, 2025 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| October 1, 2025 |
BCRX |
8-K filed: Material agreement, Other event |
Corporate |
— |
| October 1, 2025 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| October 2, 2025 |
AZN |
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) |
Trial Milestone |
Phase 3 |
| October 2, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 2, 2025 |
FDMT |
8-K filed: Leadership change |
Corporate |
— |
| October 2, 2025 |
TSHA |
8-K filed: Other event |
Filing |
— |
| October 2, 2025 |
DYN |
8-K filed: Leadership change |
Corporate |
— |
| October 2, 2025 |
CRVS |
8-K filed: Leadership change |
Corporate |
— |
| October 2, 2025 |
ANGO |
Quarterly results filed (8-K) |
Earnings |
— |
| October 2, 2025 |
TTRX |
8-K filed: Material agreement, Leadership change |
Corporate |
— |
| October 3, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 3, 2025 |
JNJ |
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma |
Trial Milestone |
Phase 1 |
| October 3, 2025 |
ABBV |
Quarterly results filed (8-K) |
Earnings |
— |
| October 3, 2025 |
INCY |
8-K filed: Leadership change |
Corporate |
— |
| October 3, 2025 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| October 3, 2025 |
ALNY |
8-K filed: Material agreement |
Corporate |
— |
| October 3, 2025 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| October 3, 2025 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| October 3, 2025 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| October 3, 2025 |
SLS |
8-K filed: Material agreement |
Corporate |
— |
| October 3, 2025 |
ALT |
8-K filed: Leadership change |
Corporate |
— |
| October 3, 2025 |
LONA |
8-K filed: Other event |
Filing |
— |
| October 3, 2025 |
HALO |
8-K filed: Material agreement |
Corporate |
— |
| October 3, 2025 |
XBIT |
8-K filed: Material agreement, Leadership change |
Corporate |
— |
| October 6, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| October 6, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 6, 2025 |
ABBV |
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder |
Trial Milestone |
Phase 3 |
| October 6, 2025 |
REGN |
Quarterly results filed (8-K) |
Earnings |
— |
| October 6, 2025 |
GILD |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 6, 2025 |
VNDA |
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use |
Trial Milestone |
Phase 2 |
| October 6, 2025 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| October 6, 2025 |
CORT |
8-K filed: Leadership change |
Corporate |
— |
| October 6, 2025 |
RCUS |
8-K filed: Other event |
Filing |
— |
| October 6, 2025 |
OCS |
6-K filed: Foreign issuer report |
Filing |
— |
| October 6, 2025 |
IVVD |
8-K filed: Other event |
Filing |
— |
| October 6, 2025 |
PHAT |
8-K filed: Leadership change |
Corporate |
— |
| October 6, 2025 |
STOK |
8-K filed: Leadership change |
Corporate |
— |
| October 6, 2025 |
CLRB |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 6, 2025 |
TRAW |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| October 6, 2025 |
ORMP |
8-K filed: Other event |
Filing |
— |
| October 6, 2025 |
VALN |
6-K/A filed: Foreign issuer report |
Filing |
— |
| October 6, 2025 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| October 6, 2025 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| October 6, 2025 |
HALO |
8-K filed: Leadership change |
Corporate |
— |
| October 6, 2025 |
IRON |
8-K filed: Leadership change |
Corporate |
— |
| October 6, 2025 |
MAZE |
8-K filed: Leadership change |
Corporate |
— |
| October 7, 2025 |
AZN |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| October 7, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 7, 2025 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| October 7, 2025 |
BMRN |
Quarterly results filed (8-K) |
Earnings |
— |
| October 7, 2025 |
HUMA |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| October 7, 2025 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| October 7, 2025 |
MAIA |
8-K filed: Other event |
Filing |
— |
| October 7, 2025 |
LXEO |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 7, 2025 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| October 7, 2025 |
ACHV |
8-K filed: Leadership change |
Corporate |
— |
| October 7, 2025 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| October 8, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 8, 2025 |
ABBV |
A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants |
Trial Milestone |
Phase 1 |
| October 8, 2025 |
KPTI |
Quarterly results filed (8-K) |
Earnings |
— |
| October 8, 2025 |
ZBIO |
Quarterly results filed (8-K) |
Earnings |
— |
| October 8, 2025 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| October 8, 2025 |
RNAC |
8-K filed: Leadership change |
Corporate |
— |
| October 8, 2025 |
LKFT |
A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus |
Trial Milestone |
Phase 2 |
| October 8, 2025 |
SPRB |
8-K filed: Material agreement, Other event |
Corporate |
— |
| October 9, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 9, 2025 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| October 9, 2025 |
BIIB |
A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND) |
Trial Milestone |
Phase 4 |
| October 9, 2025 |
AGIO |
Single and Multiple Ascending Dose Study and Food Effect Study for AG181 |
Trial Milestone |
Phase 1 |
| October 9, 2025 |
TSHA |
8-K filed: Other event |
Filing |
— |
| October 9, 2025 |
CABA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 9, 2025 |
NRIX |
Quarterly results filed (8-K) |
Earnings |
— |
| October 9, 2025 |
NGNE |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 9, 2025 |
NTHI |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| October 9, 2025 |
IRON |
Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia |
Trial Milestone |
Phase 1 |
| October 9, 2025 |
MNKD |
8-K filed: Material agreement, Acquisition completed |
Corporate |
— |
| October 9, 2025 |
EDIT |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 9, 2025 |
AGEN |
8-K filed: Material agreement |
Corporate |
— |
| October 10, 2025 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| October 10, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 10, 2025 |
PRAX |
Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET) |
Trial Milestone |
Phase 3 |
| October 10, 2025 |
SRPT |
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74) |
Trial Milestone |
Phase 1 |
| October 10, 2025 |
CLRB |
Quarterly results filed (8-K) |
Earnings |
— |
| October 10, 2025 |
ONCY |
6-K filed: Foreign issuer report |
Filing |
— |
| October 10, 2025 |
NTHI |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 11, 2025 |
INCY |
Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants |
Trial Milestone |
Phase 1 |
| October 13, 2025 |
INCY |
Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies |
Trial Milestone |
Phase 1 |
| October 13, 2025 |
IBRX |
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer |
Trial Milestone |
Phase 3 |
| October 13, 2025 |
IBRX |
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer |
Trial Milestone |
Phase 2 |
| October 13, 2025 |
MRNA |
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age |
Trial Milestone |
Phase 2 |
| October 13, 2025 |
LKFT |
A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis |
Trial Milestone |
Phase 2 |
| October 13, 2025 |
CGEM |
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer |
Trial Milestone |
Phase 1/Phase 2 |
| October 14, 2025 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| October 14, 2025 |
NVS |
Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations |
Trial Milestone |
Phase 2 |
| October 14, 2025 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| October 14, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 14, 2025 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| October 14, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 14, 2025 |
JNJ |
Quarterly results filed (8-K) |
Earnings |
— |
| October 14, 2025 |
BIIB |
Quarterly results filed (8-K) |
Earnings |
— |
| October 14, 2025 |
KPTI |
8-K filed: Material agreement, Other event |
Corporate |
— |
| October 14, 2025 |
EYPT |
Quarterly results filed (8-K) |
Earnings |
— |
| October 14, 2025 |
CADL |
Quarterly results filed (8-K) |
Earnings |
— |
| October 14, 2025 |
ANVS |
8-K filed: Material agreement, Reg FD disclosure, Other event |
Corporate |
— |
| October 14, 2025 |
RCUS |
8-K filed: Other event |
Filing |
— |
| October 14, 2025 |
DNLI |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 14, 2025 |
GERN |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| October 14, 2025 |
SRRK |
8-K filed: Other event |
Filing |
— |
| October 14, 2025 |
LRMR |
8-K filed: Other event |
Filing |
— |
| October 14, 2025 |
MAIA |
8-K filed: Material agreement, Other event |
Corporate |
— |
| October 14, 2025 |
TRAW |
8-K filed: Other event |
Filing |
— |
| October 14, 2025 |
SYRE |
Quarterly results filed (8-K) |
Earnings |
— |
| October 14, 2025 |
HALO |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 14, 2025 |
ARDX |
8-K filed: Leadership change |
Corporate |
— |
| October 14, 2025 |
BCRX |
Quarterly results filed (8-K) |
Earnings |
— |
| October 14, 2025 |
FATE |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| October 14, 2025 |
CLLS |
6-K/A filed: Foreign issuer report |
Filing |
— |
| October 14, 2025 |
ALLO |
8-K filed: Other event |
Filing |
— |
| October 14, 2025 |
APLM |
6-K filed: Foreign issuer report |
Filing |
— |
| October 15, 2025 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| October 15, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 15, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| October 15, 2025 |
REGN |
Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer |
Trial Milestone |
Phase 1 |
| October 15, 2025 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| October 15, 2025 |
QNRX |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| October 15, 2025 |
ACAD |
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome |
Trial Milestone |
Phase 3 |
| October 15, 2025 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| October 15, 2025 |
AWHL |
8-K filed: Other event |
Filing |
— |
| October 15, 2025 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| October 15, 2025 |
SYRE |
8-K filed: Material agreement |
Corporate |
— |
| October 15, 2025 |
CRSP |
8-K filed: Other event |
Filing |
— |
| October 15, 2025 |
OMER |
8-K filed: Material agreement, Other event |
Corporate |
— |
| October 15, 2025 |
XNCR |
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies |
Trial Milestone |
Phase 2 |
| October 15, 2025 |
XBIT |
8-K/A filed: Leadership change |
Corporate |
— |
| October 16, 2025 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| October 16, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 16, 2025 |
ARGX |
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function |
Trial Milestone |
Phase 2 |
| October 16, 2025 |
BIIB |
A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55 |
Trial Milestone |
Phase 1 |
| October 16, 2025 |
NBIX |
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy |
Trial Milestone |
Phase 3 |
| October 16, 2025 |
PRAX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 16, 2025 |
XENE |
8-K filed: Leadership change |
Corporate |
— |
| October 16, 2025 |
TSHA |
8-K filed: Other event |
Filing |
— |
| October 16, 2025 |
DNTH |
Quarterly results filed (8-K) |
Earnings |
— |
| October 16, 2025 |
KURA |
8-K filed: Other event |
Filing |
— |
| October 16, 2025 |
PCRX |
A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip |
Trial Milestone |
Phase 2 |
| October 16, 2025 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| October 16, 2025 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| October 16, 2025 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| October 16, 2025 |
APLM |
6-K filed: Foreign issuer report |
Filing |
— |
| October 17, 2025 |
MRK |
A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001) |
Trial Milestone |
Phase 1 |
| October 17, 2025 |
MRK |
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) |
Trial Milestone |
Phase 1/Phase 2 |
| October 17, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 17, 2025 |
JNJ |
A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease |
Trial Milestone |
Phase 2 |
| October 17, 2025 |
TAK |
A First-In-Human Study of TAK-004 in Healthy Adults |
Trial Milestone |
Phase 1 |
| October 17, 2025 |
RVMD |
8-K filed: Other event |
Filing |
— |
| October 17, 2025 |
XENE |
8-K/A filed: Leadership change, Other event |
Corporate |
— |
| October 17, 2025 |
EYPT |
8-K filed: Material agreement, Other event |
Corporate |
— |
| October 17, 2025 |
PHVS |
Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema |
Trial Milestone |
Phase 3 |
| October 17, 2025 |
PROK |
8-K filed: Material agreement |
Corporate |
— |
| October 17, 2025 |
LXEO |
Quarterly results filed (8-K) |
Earnings |
— |
| October 17, 2025 |
CLYM |
8-K filed: Other event |
Filing |
— |
| October 17, 2025 |
TRAW |
8-K filed: Leadership change |
Corporate |
— |
| October 17, 2025 |
RVPH |
8-K filed: Listing / standard notice |
Corporate |
— |
| October 17, 2025 |
IRON |
8-K filed: Other event |
Filing |
— |
| October 17, 2025 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| October 17, 2025 |
SPRB |
8-K filed: Leadership change |
Corporate |
— |
| October 17, 2025 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| October 17, 2025 |
FTH |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 17, 2025 |
GNPX |
8-K filed: Listing / standard notice, Reg FD disclosure, Other event |
Corporate |
— |
| October 18, 2025 |
RCUS |
Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29) |
Trial Milestone |
Phase 1 |
| October 20, 2025 |
AZN |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| October 20, 2025 |
AZN |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| October 20, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 20, 2025 |
ABBV |
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine |
Trial Milestone |
Phase 3 |
| October 20, 2025 |
RARE |
Setrusumab vs Placebo for Osteogenesis Imperfecta |
Trial Milestone |
Phase 2/Phase 3 |
| October 20, 2025 |
MRNA |
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age |
Trial Milestone |
Phase 3 |
| October 20, 2025 |
PRAX |
8-K filed: Other event |
Filing |
— |
| October 20, 2025 |
SMMT |
Quarterly results filed (8-K) |
Earnings |
— |
| October 20, 2025 |
VSTM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 20, 2025 |
IDYA |
8-K filed: Other event |
Filing |
— |
| October 20, 2025 |
REPL |
8-K filed: Other event |
Filing |
— |
| October 20, 2025 |
OLMA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 20, 2025 |
CRBP |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 20, 2025 |
DCTH |
Quarterly results filed (8-K) |
Earnings |
— |
| October 20, 2025 |
IMTX |
6-K filed: Foreign issuer report |
Filing |
— |
| October 20, 2025 |
PRQR |
6-K filed: Foreign issuer report |
Filing |
— |
| October 20, 2025 |
ANRO |
8-K filed: Material agreement, Other event |
Corporate |
— |
| October 20, 2025 |
ONCY |
6-K filed: Foreign issuer report |
Filing |
— |
| October 20, 2025 |
ONCY |
6-K filed: Foreign issuer report |
Filing |
— |
| October 20, 2025 |
CATX |
Quarterly results filed (8-K) |
Earnings |
— |
| October 20, 2025 |
SGMT |
A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants |
Trial Milestone |
Phase 1 |
| October 20, 2025 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| October 20, 2025 |
IRON |
Quarterly results filed (8-K) |
Earnings |
— |
| October 20, 2025 |
CRMD |
Quarterly results filed (8-K) |
Earnings |
— |
| October 21, 2025 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| October 21, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 21, 2025 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| October 21, 2025 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| October 21, 2025 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| October 21, 2025 |
INBS |
8-K filed: Leadership change |
Corporate |
— |
| October 21, 2025 |
PRAX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 21, 2025 |
QNRX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 21, 2025 |
SUPN |
Quarterly results filed (8-K) |
Earnings |
— |
| October 21, 2025 |
RNAC |
8-K filed: Leadership change |
Corporate |
— |
| October 21, 2025 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| October 21, 2025 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| October 21, 2025 |
CNSY |
8-K filed: Material agreement |
Corporate |
— |
| October 21, 2025 |
QTTB |
8-K filed: Other event |
Filing |
— |
| October 21, 2025 |
APLM |
6-K filed: Foreign issuer report |
Filing |
— |
| October 21, 2025 |
GNPX |
8-K filed: Other event |
Filing |
— |
| October 22, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| October 22, 2025 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| October 22, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 22, 2025 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| October 22, 2025 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| October 22, 2025 |
JAZZ |
8-K filed: Other event |
Filing |
— |
| October 22, 2025 |
ALKS |
Quarterly results filed (8-K) |
Earnings |
— |
| October 22, 2025 |
SMMT |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| October 22, 2025 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| October 22, 2025 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| October 22, 2025 |
BSX |
Quarterly results filed (8-K) |
Earnings |
— |
| October 22, 2025 |
KRYS |
8-K filed: Other event |
Filing |
— |
| October 22, 2025 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| October 22, 2025 |
NRIX |
8-K filed: Other event |
Filing |
— |
| October 22, 2025 |
NRIX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 22, 2025 |
OTLC |
8-K filed: Other event |
Filing |
— |
| October 22, 2025 |
TTRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 22, 2025 |
NERV |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| October 22, 2025 |
IRON |
8-K filed: Material agreement, Other event |
Corporate |
— |
| October 23, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 23, 2025 |
RARE |
Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta |
Trial Milestone |
Phase 3 |
| October 23, 2025 |
VSTM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 23, 2025 |
BSX |
8-K filed: Leadership change |
Corporate |
— |
| October 23, 2025 |
GRCE |
8-K filed: Other event |
Filing |
— |
| October 23, 2025 |
TNGX |
Quarterly results filed (8-K) |
Earnings |
— |
| October 23, 2025 |
MAIA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 23, 2025 |
BFRI |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 23, 2025 |
SGMT |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 23, 2025 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| October 23, 2025 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 23, 2025 |
WST |
Quarterly results filed (8-K) |
Earnings |
— |
| October 23, 2025 |
GNPX |
8-K filed: Other event |
Filing |
— |
| October 24, 2025 |
PFE |
A Study to Learn How the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults |
Trial Milestone |
Phase 1 |
| October 24, 2025 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| October 24, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 24, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| October 24, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| October 24, 2025 |
TEVA |
Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China |
Trial Milestone |
Phase 4 |
| October 24, 2025 |
VTRS |
8-K filed: Other event |
Filing |
— |
| October 24, 2025 |
SNDX |
8-K filed: Other event |
Filing |
— |
| October 24, 2025 |
TNGX |
8-K filed: Material agreement |
Corporate |
— |
| October 24, 2025 |
KURA |
8-K filed: Other event |
Filing |
— |
| October 24, 2025 |
MAIA |
8-K filed: Other event |
Filing |
— |
| October 24, 2025 |
BFRI |
8-K filed: Material agreement, Acquisition completed, Other event |
Corporate |
— |
| October 24, 2025 |
ORMP |
Quarterly results filed (8-K) |
Earnings |
— |
| October 24, 2025 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| October 24, 2025 |
CRIS |
8-K filed: Listing / standard notice |
Corporate |
— |
| October 24, 2025 |
XNCR |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 24, 2025 |
GNPX |
8-K filed: Material agreement, Other event |
Corporate |
— |
| October 25, 2025 |
INSM |
A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants |
Trial Milestone |
Phase 1 |
| October 27, 2025 |
NVS |
6-K filed: Foreign issuer report |
Filing |
— |
| October 27, 2025 |
GSK |
A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension |
Trial Milestone |
Phase 2 |
| October 27, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 27, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| October 27, 2025 |
BMRN |
Quarterly results filed (8-K) |
Earnings |
— |
| October 27, 2025 |
ZBIO |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 27, 2025 |
NTLA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 27, 2025 |
CABA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 27, 2025 |
PHAT |
8-K filed: Other event |
Filing |
— |
| October 27, 2025 |
IMTX |
6-K filed: Foreign issuer report |
Filing |
— |
| October 27, 2025 |
SLS |
8-K filed: Material agreement, Other event |
Corporate |
— |
| October 27, 2025 |
MAIA |
8-K filed: Other event |
Filing |
— |
| October 27, 2025 |
OGN |
8-K filed: Leadership change, Other event |
Corporate |
— |
| October 27, 2025 |
COYA |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| October 27, 2025 |
XFOR |
8-K filed: Material agreement |
Corporate |
— |
| October 27, 2025 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| October 27, 2025 |
FATE |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 28, 2025 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| October 28, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| October 28, 2025 |
NVS |
6-K filed: Foreign issuer report |
Filing |
— |
| October 28, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 28, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 28, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| October 28, 2025 |
REGN |
Quarterly results filed (8-K) |
Earnings |
— |
| October 28, 2025 |
INCY |
Quarterly results filed (8-K) |
Earnings |
— |
| October 28, 2025 |
NBIX |
Quarterly results filed (8-K) |
Earnings |
— |
| October 28, 2025 |
JAZZ |
8-K filed: Leadership change |
Corporate |
— |
| October 28, 2025 |
ALKS |
Quarterly results filed (8-K) |
Earnings |
— |
| October 28, 2025 |
ANVS |
8-K filed: Material agreement, Other event |
Corporate |
— |
| October 28, 2025 |
RCUS |
Quarterly results filed (8-K) |
Earnings |
— |
| October 28, 2025 |
VOR |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 28, 2025 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| October 28, 2025 |
KNSA |
Quarterly results filed (8-K) |
Earnings |
— |
| October 28, 2025 |
ONCY |
6-K filed: Foreign issuer report |
Filing |
— |
| October 28, 2025 |
TTRX |
8-K filed: Material agreement |
Corporate |
— |
| October 28, 2025 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| October 28, 2025 |
ALDX |
8-K filed: Other event |
Filing |
— |
| October 28, 2025 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| October 28, 2025 |
AKBA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 28, 2025 |
GNPX |
8-K filed: Other event |
Filing |
— |
| October 29, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 29, 2025 |
GSK |
Results filed (6-K) |
Earnings |
— |
| October 29, 2025 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| October 29, 2025 |
IONS |
Quarterly results filed (8-K) |
Earnings |
— |
| October 29, 2025 |
VNDA |
Quarterly results filed (8-K) |
Earnings |
— |
| October 29, 2025 |
DFTX |
Quarterly results filed (8-K) |
Earnings |
— |
| October 29, 2025 |
NTLA |
8-K filed: Other event |
Filing |
— |
| October 29, 2025 |
CABA |
8-K filed: Other event |
Filing |
— |
| October 29, 2025 |
VTGN |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| October 29, 2025 |
GKOS |
Quarterly results filed (8-K) |
Earnings |
— |
| October 29, 2025 |
CMPS |
8-K filed: Leadership change |
Corporate |
— |
| October 29, 2025 |
SVRA |
8-K filed: Material agreement, Reg FD disclosure, Other event |
Corporate |
— |
| October 29, 2025 |
OCS |
6-K filed: Foreign issuer report |
Filing |
— |
| October 29, 2025 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| October 29, 2025 |
UTHR |
Quarterly results filed (8-K) |
Earnings |
— |
| October 29, 2025 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| October 29, 2025 |
KYTX |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 29, 2025 |
KYTX |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 29, 2025 |
RXRX |
8-K filed: Other event |
Filing |
— |
| October 29, 2025 |
MPLT |
8-K filed: Other event |
Filing |
— |
| October 29, 2025 |
WVE |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 29, 2025 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| October 29, 2025 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 29, 2025 |
GNPX |
8-K filed: Material agreement, Other event |
Corporate |
— |
| October 30, 2025 |
MRK |
Quarterly results filed (8-K) |
Earnings |
— |
| October 30, 2025 |
LLY |
Quarterly results filed (8-K) |
Earnings |
— |
| October 30, 2025 |
BMY |
Quarterly results filed (8-K) |
Earnings |
— |
| October 30, 2025 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| October 30, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 30, 2025 |
TAK |
A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants |
Trial Milestone |
Phase 3 |
| October 30, 2025 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 30, 2025 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 30, 2025 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 30, 2025 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| October 30, 2025 |
GILD |
Quarterly results filed (8-K) |
Earnings |
— |
| October 30, 2025 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| October 30, 2025 |
BIIB |
Quarterly results filed (8-K) |
Earnings |
— |
| October 30, 2025 |
AGIO |
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) |
Trial Milestone |
Phase 2/Phase 3 |
| October 30, 2025 |
AGIO |
Quarterly results filed (8-K) |
Earnings |
— |
| October 30, 2025 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| October 30, 2025 |
RARE |
8-K filed: Other event |
Filing |
— |
| October 30, 2025 |
ALNY |
Quarterly results filed (8-K) |
Earnings |
— |
| October 30, 2025 |
INBS |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 30, 2025 |
INSM |
Quarterly results filed (8-K) |
Earnings |
— |
| October 30, 2025 |
LQDA |
8-K filed: Material agreement |
Corporate |
— |
| October 30, 2025 |
TVTX |
Quarterly results filed (8-K) |
Earnings |
— |
| October 30, 2025 |
BCYC |
Quarterly results filed (8-K) |
Earnings |
— |
| October 30, 2025 |
RNAC |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| October 30, 2025 |
SVRA |
8-K filed: Material agreement, Other event |
Corporate |
— |
| October 30, 2025 |
IVVD |
8-K filed: Other event |
Filing |
— |
| October 30, 2025 |
NVCR |
Quarterly results filed (8-K) |
Earnings |
— |
| October 30, 2025 |
CRBP |
8-K filed: Other event |
Filing |
— |
| October 30, 2025 |
PHAT |
Quarterly results filed (8-K) |
Earnings |
— |
| October 30, 2025 |
TTRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 30, 2025 |
NTHI |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 30, 2025 |
ARDX |
Quarterly results filed (8-K) |
Earnings |
— |
| October 30, 2025 |
OGN |
8-K/A filed: Leadership change |
Corporate |
— |
| October 30, 2025 |
WVE |
8-K/A filed: Reg FD disclosure, Other event |
Filing |
— |
| October 30, 2025 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| October 30, 2025 |
AMRX |
Quarterly results filed (8-K) |
Earnings |
— |
| October 30, 2025 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 30, 2025 |
CNSY |
Quarterly results filed (8-K) |
Earnings |
— |
| October 30, 2025 |
FTH |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 30, 2025 |
ILMN |
Quarterly results filed (8-K) |
Earnings |
— |
| October 31, 2025 |
AZN |
Study of AZD9829 in CD123+ Hematological Malignancies |
Trial Milestone |
Phase 1/Phase 2 |
| October 31, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 31, 2025 |
ABBV |
Quarterly results filed (8-K) |
Earnings |
— |
| October 31, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| October 31, 2025 |
AAPG |
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL |
Trial Milestone |
Phase 1 |
| October 31, 2025 |
FDMT |
8-K filed: Material agreement |
Corporate |
— |
| October 31, 2025 |
DFTX |
8-K filed: Material agreement, Other event |
Corporate |
— |
| October 31, 2025 |
VTGN |
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3) |
Trial Milestone |
Phase 3 |
| October 31, 2025 |
OCS |
6-K filed: Foreign issuer report |
Filing |
— |
| October 31, 2025 |
INTS |
8-K filed: Material agreement, Other event |
Corporate |
— |
| October 31, 2025 |
HURA |
8-K filed: Material agreement |
Corporate |
— |
| October 31, 2025 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| October 31, 2025 |
CELZ |
8-K filed: Material agreement |
Corporate |
— |